Staci Nason
Family · Loxahatchee, FLNPI 1508344169
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,520 and has fallen 85.4% since, to $222 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$369
- Sanofi$293
- Merck$293
- Johnson & Johnson$264
- Lilly USA, LLC$229
- Bristol Myers Squibb$202
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,27794%
- Education$2266%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $369 |
| Sanofi | 13 | $293 |
| Merck | 14 | $293 |
| Johnson & Johnson | 14 | $264 |
| Lilly USA, LLC | 10 | $229 |
| Bristol Myers Squibb | 11 | $202 |
| Daiichi Sankyo Inc. | 7 | $135 |
| Jazz Pharmaceuticals Inc. | 6 | $123 |
| Exelixis Inc. | 2 | $123 |
| Pfizer | 6 | $117 |
| Astellas Pharma US Inc | 6 | $117 |
| AstraZeneca | 6 | $107 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $106 |
| Seagen Inc. | 6 | $99 |
| AbbVie | 4 | $97 |
| Mirati Therapeutics, Inc. | 4 | $88 |
| Bayer | 5 | $87 |
| Eisai Inc. | 4 | $84 |
| Amgen | 5 | $79 |
| Incyte Corporation | 3 | $59 |
| Puma Biotechnology, Inc. | 3 | $55 |
| Beigene USA, Inc. | 3 | $47 |
| Ipsen Biopharmaceuticals, Inc | 2 | $44 |
| ADC Therapeutics America, Inc. | 2 | $33 |
| Boehringer Ingelheim | 1 | $32 |
| Dova Pharmaceuticals | 2 | $31 |
| GSK | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| EMD Serono, Inc. | 1 | $25 |
| Sobi, Inc | 1 | $23 |
| Organon | 1 | $17 |
| Mylan Institutional Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Morphosys, US Inc. | 1 | $14 |
| Blueprint Medicines Corporation | 1 | $14 |
| Global Blood Therapeutics, Inc. | 1 | $11 |
How this compares
$3,503 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anagrelide Hcl | 12 | $670 |
Paid to pharmacies, not to this prescriber.
Other family in Loxahatchee
- Rachael BuschLoxahatchee$189K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.